RNA

At a glance

Atrium Therapeutics, Inc. (RNA) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in San Diego, United States. The company is worth $131.2M. Revenue was $18.62M in fiscal 2025, up 70.9% from the year before. It reported a net loss of $76.68M. The share price is 54.3% below its 52-week high of $16.77. 5 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Two Sigma (Two Sigma Investments), at $4.65M. In that quarter, 2 of them opened or added to the position. No open-market insider trades in it were filed over the last 30 days.

Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.

Key metrics

Market cap

$131.2M

P/E

—

Forward P/E

—

P/B

0.6x

Dividend yield

0.00%

Payout

—

EPS

-$5.44

ROE

—

Profit margin

-184.15%

Revenue growth

-21.90%

Beta

—

52-week high

$16.77

52-week low

$7.54

History

Year by year, from the annual reports; dividends from the payments themselves.

Investors holding this

Major managers that reported this stock in their latest 13F.

• TS
  Two Sigma+ Added

  Two Sigma Investments · Q2 2026
  $4.65M

  345.48K shares · 0.0% of portfolio
• IE
  Israel EnglanderHeld

  Millennium Management · Q2 2026
  $2.7M

  200.56K shares · 0.0% of portfolio
• CA
  Cliff Asness+ New position

  AQR Capital Management · Q2 2026
  $2.32M

  172.24K shares · 0.0% of portfolio

Others in the same sector

Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.

About the company